Abstract:Sample hemolysis is conventionally defined as the presence of a variable amount of cell-free hemoglobin in serum or plasma. The reference (i.e. “normal”) concentration of free and measurable hemoglobin conventionally ranges between 0.22 and 0.25 g/L in serum and between 0.10 and 0.13 g/L in plasma, respectively [1]. Although no definitive evidence exists about the threshold of “pathological” hemolysis in blood samples, universal consensus has been reached that clinically significant interference for the most hemolysis-vulnerable tests (i.e. potassium, lactate dehydrogenase, aspartate aminotransferase) may start with concentrations of cell-free hemoglobin ≥0.5 g/L [2, 3]. Notably, this cut-off is also conventionally used for monitoring phlebotomy practice [4]. Although the very first studies about the impact of sample hemolysis on the quality of laboratory testing have been published more than 40 years ago [5], the frequency of hemolyzed samples remains high and generates remarkable challenges in clinical laboratory practice [6–8]. The first important issue is distinguishing between in vitro (i.e. spurious) and in vivo (i.e. hemolytic anemia) hemolysis. The differentiation between these conditions is not meaningless because the former case reflects a kaleidoscope of problems emerging throughout preanalytical sample management, thus including blood drawing, handling, transportation, storage and preparation for testing, whilst the latter mirrors a life-threatening condition, which must be timely communicated to the clinicians for adopting the most appropriate care options. According to this perspective, the second and almost consequential aspect is the need of systematically monitoring sample quality for accurate and rapid identification of hemolysis in serum or plasma, as also currently endorsed by many international accreditation standards such as the International Standards Organization (ISO) 15189:2012 and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) [9]. The most obvious consequence is that all laboratories should adopt a reliable strategy for systematic monitoring of sample quality and, moreover, for identifying the presence of, and quantifying, cell-free hemoglobin in either serum or plasma. In this issue of the journal, we publish an interesting study aimed to assess whether visual inspection of sample hemolysis by comparison with a color chart, rather than automatic assessment of serum or plasma indices, may have an impact on patient safety [10]. Interestingly, the authors concluded that nearly one-third of test results generated with manual handling of hemolyzed specimens were incorrectly managed, mainly for incorrect release of hemolysis-sensitive tests results or for unnecessary suppression of data in specimens with non-clinically significant degrees of hemolysis. In both cases, these circumstances may seriously jeopardize the managed care because release of data biased for the presence of hemolysis may then trigger inappropriate therapeutic options (i.e. administration of potassium-lowering therapy in patients with “spurious” hyperkalemia), whereas unjustified test suppression may delay both diagnosis and treatment of potentially fatal diseases (i.e. delayed or inappropriate management of arrhythmias due to underdiagnosis of in vivo hyperkalemia). Color vision is conventionally defined as the capability of distinguishing colors according to the wavelengths of light reflected, emitted or transmitted. The individual ability to identify colors and perceiving their intensity depends on multiple factors, such as the local environment and its relative light exposure, but may also relay on some genetic (i.e. Opsin gene polymorphisms), anatomic and pathological aspects, which ultimately make the eyes of one subject more capable than others (color blindness, also known as “daltonism”, is a paradigmatic example) (Figure 1) [11, 12]. All these factors make color recognition rather heterogeneous in different environments and among different individuals, thus supporting the hypothesis that visual assessment of sample quality may be highly inaccurate. Previous and highly reliable evidence has been provided that visual detection of hemolyzed samples is more inaccurate compared with automatic detection [13, 14], thus paving the way to adopting more precise and standardized approaches. The current generation of preanalytical platforms and

Lipaemic plasma: An objective non‐invasive photometric method to classify plasma turbidity and its association with red cell haemolysis

Spectrophotometric evaluation of hemolysis in plasma by quantification of free oxyhemoglobin, methemoglobin, and methemalbumin in presence of bilirubin

Lipid ratios as a marker for red blood cell storage quality and as a possible explanation for donor gender differences in storage quality

Proteomic analysis of red blood cells from donors exhibiting high hemolysis demonstrates a reduction in membrane-associated proteins involved in the oxidative response

Intravenous lipid emulsion interference in coagulation testing: an ex vivo analysis

Label‐Free Analysis of Red Blood Cell Storage Lesions Using Imaging Flow Cytometry

Variation of Hemoglobin Detection for Lipemic Blood Samples

Cell population data in venous thrombo-embolism and erysipelas: a potential diagnostic tool?

Comparison of manual titrations to automated microplate and gel titration assays used in the screening of blood donors for production of Low‐Titer O Whole Blood

Automated Measurement of Plasma Cell-Free Hemoglobin Using the Hemolysis Index Check Function

The Method of Lipemia Clearance Should be Based on the Characteristics and the Method of Testing in the Emergency Laboratory

Visual assessment of sample quality: quo usque tandem?

Cherry-red plasma: Beyond the assumption of hemolysis

Inadvertent omission of a specimen integrity comment – an overlooked post-analytical error

Hemolysis Index Correlations with Plasma-Free Hemoglobin and Plasma Lactate Dehydrogenase in Critically Ill Patients under Extracorporeal Membrane Oxygenation or Mechanical Circulatory Support—A Single-Center Study

Spectral Analysis Methods Based on Background Subtraction and Curvature Calculation Used in the Detection or Quantification of Hemolysis and Icterus in Blood-derived Clinical Samples

Accuracy of the HemoCue® to measure cell-free plasma hemoglobin and detect clinically significant hemolysis

Assessment of the soluble proteins HMGB1, CD40L and CD62P during various platelet preparation processes and the storage of platelet concentrates: The BEST collaborative study

Reexamination of the chromium-51-labeled posttransfusion red blood cell recovery method

Supernatant protein biomarkers of red blood cell storage hemolysis as determined through an absolute quantification proteomics technology

Practical recommendations for managing hemolyzed samples in clinical chemistry testing